LabGenius and Sanofi Collaborate on Multiple AI/ML-Driven Antibody Optimization Programs for Inflammation Treatments.
ByAinvest
Thursday, Dec 4, 2025 3:05 am ET1min read
SNY--
LabGenius Therapeutics has announced a new collaboration with Sanofi to co-optimize proteins for therapeutic properties using their AI/ML-driven antibody design capabilities. This partnership will focus on optimizing NANOBODY molecules for multiple new targets in inflammation. LabGenius' CSO, Dr. Angus Sinclair, expressed excitement about the collaboration, citing its validation of the company's platform and potential for better patient outcomes.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet